Needham & Company Reiterates Buy on Alnylam Pharmaceuticals (ALNY), Says Stock Undervalued

Article Stock Quotes (1) Comments (0)

Needham & Company reiterated their Buy rating on Alnylam Pharmaceuticals (NASDAQ: ALNY) and price target of $20.00.

Alnylam management reviewed 2Q12 in a conference call after market close yesterday. During the call, they announced new preclinical data supporting feasibility of subcutaneous administration of RNAi. Given the encouraging data, management guided for ALN-TTRsc IND submission in 2H12 and ALN-AT3 IND submission in 2013, said analyst Alan Carr in a research note today.

"Overall, we are impressed by the consistency in safety, PK, and efficacy profiles of the company’s candidates across preclinical models and in human trials. We believe the stock is undervalued," added Carr.

For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.

Shares of Alnylam Pharmaceuticals closed at $18.44 yesterday, with a 52 week range of $5.88-$20.63.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Wedbush Downgrades XenoPort (XNPT) to Neutral
• Wall Street Expresses Tepid Enthusiasm on Yahoo! (YHOO) / Tumblr Deal
• Biogen (BIIB) Weeks-6 TECFIDERA Scripts Continue to Ramp

Create E-mail Alert Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Needham & Company

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?